Startup aims to churn out other orphan drug startups

04/25/2013 | Xconomy

Armed with $16 million in venture capital, former MedImmune boss David Mott's new enterprise Cydan will find and fund small firms with promising orphan drug candidates. Investor return will be through licensing deals with or acquisition by larger drugmakers. Mott plans to collaborate with parent and patient advocacy groups and will subcontract toxicology, pharmacology and other testing to reduce development risk.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ